Glax­o­SmithK­line of­fers fill-fin­ish ca­pac­i­ty to No­vavax for UK sup­ply of Covid-19 vac­cine

UK drug­mak­er Glax­o­SmithK­line has tak­en a broad re­sponse to the Covid-19 pan­dem­ic, work­ing on both vac­cines and ther­a­peu­tics. So far, that strat­e­gy hasn’t churned out much suc­cess — but the drug­mak­er is still sign­ing deals, this time with vac­cine play­er No­vavax.

GSK will chip in on pro­duc­ing No­vavax’s re­com­bi­nant Covid-19 vac­cine, pledg­ing fill-fin­ish ca­pac­i­ty for 60 mil­lion dos­es of the shot for use in the UK as part of a deal with the Mary­land biotech and the UK gov­ern­ment an­nounced Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER